GLP-1 Pills: How Oral Semaglutide and Orforglipron Compare

For most of the GLP-1 era the answer to “is there a pill?” was no. That changed twice in four months: the FDA approved the Wegovy pill on 22 December 2025 and Foundayo on 1 April 2026.

Both are once-daily tablets for weight management. They are not the same kind of drug, and the numbers being quoted for them are not the same kind of number.

What are the two GLP-1 pills?

Oral semaglutide (Wegovy pill, 25 mg) is the same peptide as injectable semaglutide, made absorbable by pairing it with SNAC, an absorption enhancer that lets it cross the stomach lining. It was approved to reduce excess body weight, maintain that reduction long term, and reduce the risk of major adverse cardiovascular events.

Orforglipron (Foundayo) is a different proposition — a small molecule, not a peptide. It activates the same receptor without being a protein, which is why it does not need an absorption enhancer or a fasting window. It comes in 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg tablets, and was approved for adults with obesity, or overweight with weight-related medical problems, alongside reduced-calorie diet and increased physical activity.

That structural difference is the same one that explains why injectable GLP-1s were engineered the way they were — see why engineered GLP-1 drugs last a week.

How much weight do they actually cause people to lose?

This is where the reporting gets slippery, and it is worth slowing down.

Clinical trials report results under a chosen estimand — a formal statement of which question the number answers. Two are common:

The treatment-regimen (or intention-to-treat) estimand: what happened across everyone randomised, including people who stopped the drug or never got to the top dose.
The efficacy or trial product estimand: what the effect would have been if everyone had stayed on treatment as directed.

The second number is always the larger one. Neither is dishonest; they answer different questions, and only one of them describes what happens to a real population of patients.

	Wegovy pill (oral semaglutide 25 mg)	Foundayo (orforglipron)
Trial	OASIS 4, 64 weeks, 307 adults	ATTAIN-1, 72 weeks, 3,127 adults
If everyone adhered	16.6% (trial product estimand)	12.4% vs 0.9% placebo
Regardless of adherence	not reported in the announcement	11.1% vs 2.1% placebo
≥20% weight loss	about one in three	—

Novo Nordisk published only the adherence-conditioned figure for OASIS 4, and footnotes it plainly as “the treatment effect if all people adhered to treatment.” Lilly published both. Setting 16.6% beside 11.1% is not a comparison of two drugs — it is a comparison of two questions.

Note also what happens to the placebo arms: 0.9% under the efficacy estimand, 2.1% under the treatment-regimen one. The drug-minus-placebo difference for orforglipron is 11.5 points one way and 9.0 points the other. The estimand moves both columns, which is precisely why mixing them across products produces a misleading gap.

There is a second asymmetry worth flagging: OASIS 4 randomised 307 people and ATTAIN-1 randomised 3,127. A trial ten times larger supports a narrower confidence interval, independent of which drug performed better.

So which one is stronger?

On the evidence as published, oral semaglutide’s adherence-conditioned result is higher than orforglipron’s adherence-conditioned result — 16.6% against 12.4%. That is the only pairing that compares like with like, and it favours semaglutide.

What cannot be said from these two announcements is how they compare in ordinary use, because only one of them reported that. No head-to-head trial has been published.

Which is easier to take?

Here orforglipron has the clearer advantage, and it is a practical one rather than a statistical one.

Oral semaglutide must be taken on an empty stomach in the morning with no more than four ounces of plain water, swallowed whole, with at least 30 minutes before eating, drinking, or taking any other oral medication. That window exists because absorption depends on SNAC working in an empty stomach.

Orforglipron is taken once daily with or without food, at any time of day. For anyone on morning medications or with an unpredictable schedule, that difference may matter more than a few percentage points — a dose not taken has an effect size of zero.

What are the side effects?

Both are GLP-1 receptor agonists and both behave like it. Reported adverse events for orforglipron include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss. Oral semaglutide’s most common reactions are nausea, vomiting, and diarrhea.

Both carry a boxed warning for thyroid C-cell tumors, consistent with the injectable GLP-1 class. The broader side-effect picture is covered in GLP-1 side effects: what the trials report, and the reason titration is slow in GLP-1 dosing and titration.

Frequently asked questions

Is there a GLP-1 pill?

Yes — two. Oral semaglutide (Wegovy pill, 25 mg) was FDA approved on 22 December 2025, and orforglipron (Foundayo) on 1 April 2026. Both are once-daily tablets for weight management.

Is the GLP-1 pill as good as the injection?

Novo Nordisk states that the weight loss with the Wegovy pill is similar to that with injectable Wegovy 2.4 mg. That comparison is drawn across separate trials rather than a head-to-head, so it is a reasonable expectation rather than a demonstrated equivalence.

Is Rybelsus the same as the Wegovy pill?

No. Rybelsus is oral semaglutide at 7 and 14 mg, approved for type 2 diabetes. The Wegovy pill is the same molecule at 25 mg with an obesity and cardiovascular indication. Same drug, different dose and different approved use.

Do I have to take a GLP-1 pill on an empty stomach?

For oral semaglutide, yes — empty stomach, up to four ounces of water, 30 minutes before anything else by mouth. Orforglipron has no such restriction and can be taken with or without food at any time of day.

Is a pill cheaper than the injection?

Not necessarily, and pricing changes faster than any article can track. Oral formulations do not automatically cost less to manufacture or to buy. What each route costs today is broken down in GLP-1 cost: what you actually pay, and the longer-term outlook in generic GLP-1s: when will prices fall?.

The takeaway

Two GLP-1 pills now exist, which removes the needle as a barrier for people for whom it was one. That is a real change.

What has not changed is the need to read the numbers carefully. The 16.6% attached to oral semaglutide describes what happens when everyone takes the drug as directed, and it is labelled that way at the source. Orforglipron’s 11.1% describes what happened across everyone randomised. Putting those two figures side by side overstates the distance between the drugs, and the honest comparison — 16.6% against 12.4% — is narrower.

Approval status and pricing in this class both move quickly, and neither this page nor any other substitutes for a prescriber who knows your history.